# A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

> **NCT00942578** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 63 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Lenalidomide
- **DRUG:** Docetaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00942578
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-16
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-07-31
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00942578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00942578, "A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00942578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*